These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 1912029

  • 21. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group.
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [Abstract] [Full Text] [Related]

  • 22. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [Abstract] [Full Text] [Related]

  • 23. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 24. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
    Kc D, Falchi L, Verstovsek S.
    Ann Hematol; 2017 Oct 06; 96(10):1595-1604. PubMed ID: 28808761
    [Abstract] [Full Text] [Related]

  • 25. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH.
    Semin Thromb Hemost; 2006 Sep 06; 32(6):589-604. PubMed ID: 16977569
    [Abstract] [Full Text] [Related]

  • 26. [Clinical Analysis of Gene Mutation and Vascular Events in Patients with BCR/ABL Negative Myeloproliferative Neoplasms].
    Hu BD, Chen L.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun 06; 30(3):813-818. PubMed ID: 35680810
    [Abstract] [Full Text] [Related]

  • 27. Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot Study.
    Krečak I, Pivac L, Holik H, Perić MM, Zekanović I, Čubrić E, Skelin M, Lucijanić M.
    Pharmacology; 2024 Jun 06; 109(2):110-114. PubMed ID: 38171342
    [Abstract] [Full Text] [Related]

  • 28. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC, Yeon SH, Lee MW, Ryu H, Lee HJ, Yun HJ, Kim SY, Jo DY.
    Korean J Intern Med; 2021 Sep 06; 36(5):1190-1203. PubMed ID: 34289585
    [Abstract] [Full Text] [Related]

  • 29. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency.
    Aladağ E, Aksu S, Demiroğlu H, Sayınalp N, Göker H, Haznedaroğlu İC, Özcebe Oİ, Büyükaşık Y.
    Turk J Med Sci; 2019 Oct 24; 49(5):1560-1563. PubMed ID: 31652037
    [Abstract] [Full Text] [Related]

  • 30. Erythromelalgia--a thrombotic complication in chronic myeloproliferative disorders.
    Tarach JS, Nowicka-Tarach BM, Matuszek B, Nowakowski A.
    Med Sci Monit; 2000 Oct 24; 6(1):204-8. PubMed ID: 11208311
    [Abstract] [Full Text] [Related]

  • 31. [State-of-the-art management for essential thrombocythemia and polycythemia vera].
    Sugimoto Y.
    Rinsho Ketsueki; 2021 Oct 24; 62(8):1050-1059. PubMed ID: 34497191
    [Abstract] [Full Text] [Related]

  • 32. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar 24; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 33. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
    Hernández-Boluda JC, Gómez M.
    Eur J Haematol; 2015 Jan 24; 94(1):4-11. PubMed ID: 24814134
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Uncontrolled thrombocytosis in chronic myeloproliferative disorders.
    Kessler CM, Klein HG, Havlik RJ.
    Br J Haematol; 1982 Jan 24; 50(1):157-67. PubMed ID: 6976793
    [Abstract] [Full Text] [Related]

  • 37. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.
    Tefferi A, Elliott M.
    Semin Thromb Hemost; 2007 Jun 24; 33(4):313-20. PubMed ID: 17525888
    [Abstract] [Full Text] [Related]

  • 38. Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: a retrospective study of 108 patients.
    Grossi A, Rosseti S, Vannucchi AM, Rafanelli D, Ferrini PR.
    Clin Lab Haematol; 1988 Jun 24; 10(2):167-75. PubMed ID: 3416575
    [Abstract] [Full Text] [Related]

  • 39. The risk of thrombosis in essential thrombocythemia and polycythemia vera.
    Pearson TC.
    Semin Oncol; 2002 Jun 24; 29(3 Suppl 10):16-21. PubMed ID: 12096353
    [Abstract] [Full Text] [Related]

  • 40. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution.
    Sánchez-Luceros A, Meschengieser SS, Woods AI, Blanco AN, Kempfer AC, Casais P, Salviú MJ, Lazzari MA.
    Haematologica; 2002 Mar 24; 87(3):264-70. PubMed ID: 11869938
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.